Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

Harness the power of data to map new patient pathways

Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset

Wilmington Healthcare

- PMLiVE

What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

How fantastic is it to see that the National Organisation for Rare Disorders (NORD) has followed up on a survey undertaken in the late 80’s to pressure test progress and identify...

OPEN Health

- PMLiVE

PMEA Awards 2020

Watch the event live from 4pm today – join us at www.pmlive.com/pmea2020

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

- PMLiVE

Pfizer doses first patient in investigational haemophilia drug trial

Company is evaluating marstacimab in severe haemophilia A/B patients

- PMLiVE

WHO director-general says urgent support is needed for COVAX facility

Immediate funding support totalling $4.3bn is required

- PMLiVE

FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting

Independent experts will discuss EUA submission for mRNA-based vaccine

- PMLiVE

Rethinking our approach to infectious disease preparedness

The importance of long-term strategic investment to prepare for the next threat that emerges

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

- PMLiVE

Laurence Bannister joins Lucid Group as its new Chief Commercial Officer

Laurence brings a track record of success from 22 years’ experience in pharmaceuticals/healthcare – across affiliate, regional and global commercial roles – with the last 9 years being at STEM...

Lucid Group Communications Limited

- PMLiVE

UK could approve Pfizer’s COVID-19 vaccine this week

The Telegraph reported the possible timeframe on Sunday

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

Drug approved to treat high-risk patients with mild to moderate COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links